{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T17:08:27Z","timestamp":1793207307453,"version":"4.5.0"},"reference-count":9,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2020,9,8]]},"DOI":"10.1001\/jama.2020.10155","type":"journal-article","created":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T16:31:45Z","timestamp":1597854705000},"page":"993","source":"Crossref","is-referenced-by-count":60,"title":["Polymyalgia Rheumatica and Giant Cell Arteritis"],"prefix":"10.1001","volume":"324","author":[{"given":"Frank","family":"Buttgereit","sequence":"first","affiliation":[{"name":"Charit\u00e9 University Medicine, Department of Rheumatology and Clinical Immunology, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L.","family":"Matteson","sequence":"additional","affiliation":[{"name":"Mayo Clinic College of Medicine and Science, Division of Rheumatology, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Dejaco","sequence":"additional","affiliation":[{"name":"Medical University Graz, Department of Rheumatology and Immunology, Graz, Austria"},{"name":"Hospital of Brunico (SABES-ASDAA), Department of Rheumatology, Brunico, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"22","key":"jit200019r1","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1001\/jama.2016.5444","article-title":"Polymyalgia rheumatica and giant cell arteritis: a systematic review.","volume":"315","author":"Buttgereit","year":"2016","journal-title":"JAMA"},{"issue":"2","key":"jit200019r2","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.semarthrit.2017.04.001","article-title":"Contemporary prevalence estimates for giant cell arteritis and polymyalgia rheumatica, 2015.","volume":"47","author":"Crowson","year":"2017","journal-title":"Semin Arthritis Rheum"},{"issue":"11","key":"jit200019r3","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1093\/rheumatology\/kex376","article-title":"Use of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of polymyalgia rheumatica.","volume":"57","author":"Henckaerts","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"jit200019r4","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1002\/art.v71.8","article-title":"Diagnostic accuracy of positron emission tomography\/computed tomography of the head, neck, and chest for giant cell arteritis.","volume":"71","author":"Sammel","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"jit200019r5","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1002\/acr.23320","article-title":"Comparable rates of glucocorticoid-associated adverse events in patients with polymyalgia rheumatica and comorbidities in the general population.","volume":"70","author":"Shbeeb","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"jit200019r6","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant-cell arteritis.","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"issue":"10031","key":"jit200019r7","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1016\/S0140-6736(16)00560-2","article-title":"Tocilizumab for induction and maintenance of remission in giant cell arteritis.","volume":"387","author":"Villiger","year":"2016","journal-title":"Lancet"},{"issue":"9","key":"jit200019r8","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1093\/rheumatology\/kez091","article-title":"Risk of relapse after discontinuation of tocilizumab therapy in giant cell arteritis.","volume":"58","author":"Adler","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"jit200019r9","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/art.v69.4","article-title":"A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis.","volume":"69","author":"Langford","year":"2017","journal-title":"Arthritis Rheumatol"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2770392\/jama_buttgereit_2020_it_200019_1599242807.07847.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T15:04:18Z","timestamp":1599577458000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2770392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,8]]},"references-count":9,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,9,8]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2020.10155","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,8]]}}}